Literature DB >> 6197456

Prophylactic immunization against experimental leishmaniasis. II. Further characterization of the protective immunity against fatal Leishmania tropica infection induced by irradiated promastigotes.

J G Howard, F Y Liew, C Hale, S Nicklin.   

Abstract

The genetic vulnerability of BALB/c mice to Leishmania tropica (L. major) infection renders them incapable of controlling a primary cutaneous lesion that leads to uniformly fatal visceral disease. Potent, long-lasting protection involving both lesion healing and survival can be induced by repeated prophylactic i.v. immunization with gamma-irradiated (150K rad) L. tropica promastigotes. The effect is not dependent on continuing viability or cellular invasiveness of the irradiated parasites because their effective immunogenicity withstands heating at 56 degrees C for 1 hr. Immunity is not stage specific and encompasses both amastigote and promastigote challenges. Similar prophylaxis can be induced by immunization with heterologous irradiated L. donovani promastigotes. Repeated i.v. immunization with irradiated L. tropica promastigotes induces an antibody response in the isotype sequence M leads to G1/G3 leads to G2a/G2b leads to A with substantially higher titres than are found in response to the infection itself. Splenectomy before immunization drastically reduces this antibody response without incurring any impairment of the extent of protection. Passive transfer of large amounts (up to 10 ml) of hyperimmune serum (or isotype fractions thereof) throughout the first 8 wk of infection fails to arrest disease progression during this period. Despite the previously described lack of any detectable cutaneous DTH reactivity, which has hitherto correlated with protective cell-mediated immunity, the results obtained do not support attribution of an alternative causal role to the humoral response.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6197456

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Use of an attenuated leishmanial parasite as an immunoprophylactic and immunotherapeutic agent against murine visceral leishmaniasis.

Authors:  S Mukhopadhyay; S Bhattacharyya; R Majhi; T De; K Naskar; S Majumdar; S Roy
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

Review 2.  New aspects of vaccine development.

Authors:  F Y Liew
Journal:  Clin Exp Immunol       Date:  1985-11       Impact factor: 4.330

3.  Vaccine-induced immunity against cutaneous leishmaniasis in BALB/c mice.

Authors:  D Frommel; B W Ogunkolade; I Vouldoukis; L Monjour
Journal:  Infect Immun       Date:  1988-04       Impact factor: 3.441

4.  Specific immunization of mice against Leishmania mexicana amazonensis using solubilized promastigotes.

Authors:  M Barral-Netto; S G Reed; M Sadigursky; G Sonnenfeld
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

5.  Histopathologic changes induced by vaccination in experimental cutaneous leishmaniasis of BALB/c mice.

Authors:  M Barral-Netto; L A de Freitas; Z A Andrade
Journal:  Am J Pathol       Date:  1987-05       Impact factor: 4.307

Review 6.  Leishmaniasis: current status of vaccine development.

Authors:  E Handman
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

7.  Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability.

Authors:  Susana Mendez; Khaled Tabbara; Yasmine Belkaid; Sylvie Bertholet; Daniela Verthelyi; Dennis Klinman; Robert A Seder; David L Sacks
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

8.  Membrane glycoprotein M-2 protects against Leishmania amazonensis infection.

Authors:  J Champsi; D McMahon-Pratt
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

9.  Induction of delayed-type hypersensitivity to Leishmania major and the concomitant acceleration of disease development in progressive murine cutaneous leishmaniasis.

Authors:  J S Dhaliwal; F Y Liew
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

10.  Specific suppressor T cells for delayed-type hypersensitivity in susceptible mice immunized against cutaneous leishmaniasis.

Authors:  J S Dhaliwal; F Y Liew; F E Cox
Journal:  Infect Immun       Date:  1985-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.